DeutschNewstral
Article
jdsupra.com on 2024-01-19 20:48
Federal Court finds PMPRB reasonably concluded Galderma’s patent claiming 0.3% adapalene “pertained to” 0.1% adapalene DIFFERIN
Related news
- 2021 PMPRB Annual Reportjdsupra.com
- PMPRB releases three new NPDUIS reportsjdsupra.com
- PMPRB publishes annual Meds Pipeline Monitor reportjdsupra.com
- FCA remits pricing decision on ALEXION’S SOLIRIS to PMPRBjdsupra.com
- Few significant changes made in final PMPRB Guidelinesjdsupra.com
- New PMPRB Guidelines will not be implemented January 1, 2023jdsupra.com
- PMPRB adopts Amended Interim Guidance pending release of new guidelinesjdsupra.com
- On redetermination, PMPRB concludes that Galderma’s patent ‘pertains to’ DIFFERINjdsupra.com
- PMPRB releases 2020 Annual Report and April 2022 NEWSletterjdsupra.com
- Innovators challenge final PMPRB Guidelines in new Federal Court applicationjdsupra.com
- PMPRB finds ultra-rare drug PROCYSBI is excessively pricedjdsupra.com
- PMPRB releases analytic study of Canadian oncology marketjdsupra.com
- PMPRB releases 2022 Annual Report and March 2024 NEWSletterjdsupra.com
Red-light camera grace period goes from 0.1 to 0.3 seconds, Chicago to lose $17MArs Technica
GBTC profit-taking almost concluded, JPMorgan sayscoinjournal.net- PMPRB News: “significant changes” to be made to draft pricing Guidelinesjdsupra.com
- May 1 deadline to seek leave to intervene in PMPRB SOLIRIS rehearingjdsupra.com
- Federal Court of Appeal dismisses appeal challenging amended basket of comparator countries in PMPRB Regulationsjdsupra.com
- PMPRB publishes scoping paper for consultation on guidelines, and invites stakeholder feedbackjdsupra.com
- Drug pricing in Canada: Changes for the PMPRB with proposed amendments to the Patented Medicines Regulationsjdsupra.com